Composite vaccine adjuvant, vaccine containing adjuvant, preparation method and application
By using pig GM-CSF protein and astragalus polysaccharides as vaccine adjuvants, the immune effect of the pseudorabies virus vaccine is enhanced, and the problem of insufficient immune protection against mutant strains is solved, achieving more efficient immune protection and reducing immunity The effect of the number of times.
Patent Information
- Application Number
- CN202411051506.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-19
AI Technical Summary
The existing pseudorabies virus vaccine has insufficient immune protection against new epidemic mutant strains, resulting in immunization failure. The inactivated vaccine requires multiple strengthening of immunization, making it difficult to provide complete and effective protection.
Porcine GM-CSF protein and Astragalus polysaccharides are used as complex vaccine adjuvants to stimulate humoral immune responses and produce high levels of specific gB protein antibodies and CD4+ and CD8+ T cell proliferation responses, significantly improving the humoral immune efficacy of inactivated vaccines and enhancing pseudo-sampling The immune effect of rabies virus vaccine.
It improves the immune protection effect of inactivated vaccines, reduces the amount and frequency of immunity, provides effective control and preventive protection of pseudorabies virus, and has high practical value.
Smart Images

Figure CN118976104A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of vaccine adjuvants, and in particular to a composite vaccine adjuvant, a vaccine containing the adjuvant, and a preparation method and application thereof. Background Art
[0002] Pseudorabies (PR), also known as Ojeski's disease, is a highly contagious disease caused by pseudorabies virus (PRV). PRV is a member of the Albuminae subfamily. This virus can infect a variety of mammals, including cattle, sheep, dogs, cats and rabbits, but the natural host of PRV is pigs. It is highly pathogenic and can cause severe neurorespiratory symptoms and acute febrile death, causing huge economic losses to the pig industry. Vaccination is an effective way to control PRV infection. However, since 2011, some of the Bartha-k61 attenuated vaccines in my country have not provided sufficient immune protection against the newly prevalent mutant strains in pig herds, resulting in immune failure. Compared with traditional PRV strains, mutant strains have stronger virulence and higher mortality. Therefore, it is necessary to develop more effective vaccines based on existing PRV mutant strains to control the spread of PRV.
[0003] At present, the main way to control and prevent PRV mutant strains is to vaccinate with gene-deficient live vaccines or inactivated vaccines. A single immunization with the modified live vaccine achieves the ideal PRV attack protection effect. However, live vaccines have the risk of mutation. Although inactivated vaccines do not have this risk, they cannot provide completely effective protection and usually require multiple booster immunizations. Therefore, it is necessary to develop new adjuvants to improve the immune protection effect of inactivated PRV vaccines in order to reduce the amount and frequency of immunizations. Summary of the invention
[0004] In view of the above problems existing in the pseudorabies vaccine in the prior art, the present invention provides a vaccine adjuvant, a vaccine containing the adjuvant, and a preparation method and application thereof. The vaccine adjuvant provided by the present invention uses porcine GM-CSF protein and astragalus polysaccharide as immune adjuvants, can effectively enhance and maintain the production of neutralizing antibodies, effectively improve the humoral immune efficacy of inactivated vaccines, has a good immune enhancement effect on porcine pseudorabies virus inactivated vaccines, can be applied to various types of vaccine preparations, is a potential ideal vaccine adjuvant, and has high practical value.
[0005] In order to solve the above technical problems, the technical solution provided by the present invention is:
[0006] In a first aspect, the present invention provides a composite vaccine adjuvant, comprising porcine GM-CSF protein and astragalus polysaccharide, wherein the amino acid sequence of the porcine GM-CSF protein is shown in SEQ ID NO:1.
[0007] Compared with the prior art, the present invention uses porcine GM-CSF protein and astragalus polysaccharide as immune adjuvants, which can effectively stimulate the body's humoral immune response and produce a high level of specific gB protein antibodies, and at the same time, can also induce stronger CD4 + and CD8 + The T cell proliferation response was mainly manifested by the significant increase in the expression levels of IL-2, IL-4, IL-10, and IFN-γ. The results of the serum neutralization test showed that the pseudorabies vaccine containing the composite adjuvant can induce the body to produce a high level of neutralizing antibodies, and the highest neutralization titer is 1:128. The results of the plaque test showed that the combined application of the composite adjuvant pGM-CSF and astragalus polysaccharide in the pseudorabies virus vaccine can enhance and maintain the production of neutralizing antibodies, effectively improve the humoral immune efficacy of the inactivated vaccine, and significantly enhance the immune effect of the pseudorabies virus vaccine, providing effective protection for the future control and prevention of pseudorabies virus, and has high practical value.
[0008] It should be noted that the porcine GM-CSF protein in the present invention refers to the recombinant protein expressed from granulocyte-macrophage colony-stimulating factor (pGM-CSF).
[0009] Specifically, the amino acid sequence of the porcine GM-CSF protein is as follows:
[0010] SISAPTRPPSPVTRPWQHVDAIKEALSLLNNSNDTAAVMNETVDVVCEM FDPQEPTCVQTRLNLYKQGLRGSLTRLKSPTLLAKHYEQHCPLTEETSCETQ SITFKSFKDSLNKFLFTIPFDCWGPVKK (SEQ ID NO: 1).
[0011] Furthermore, the method for preparing the porcine GM-CSF protein comprises the following steps: recombining the gene sequence expressing the porcine GM-CSF protein into an expression plasmid to obtain a recombinant plasmid; and transforming the recombinant plasmid into an expression cell for expression to obtain the porcine GM-CSF protein.
[0012] The method for preparing the porcine GM-CSF protein provided by the present invention is simple and easy to operate, has good reproducibility, has a large expression amount of the exogenous protein, low toxicity and high activity, and provides better material guarantee for the subsequent preparation of vaccine adjuvants.
[0013] Furthermore, the gene sequence expressing the porcine GM-CSF protein is shown in SEQ ID NO: 2, which is as follows:
[0014] AGCATCTCTGCGCCTACCCGTCCGCCGTCCCCAGTAACCCGCCCGTGGCAGCATGTGGACGCTATCAAAGAGGCGCTGAGCCTGCTGAATAACTCCAACGACACCGCGGCCGTGATGAACGAAACCGTTGACGTAGTGTGCGAGATGTTCGATCCGCAGGAACCGACGTGTGTACAGACGCGCCTGAACCTGTACAA ACAAGGTCTGCGTGGTTCTCTGACTCGTCTGAAGTCTCCGCTGACCCTGCTGGCGAAACACTATGAACAGCACTGCCCGCTGACTGAAGAAACTAGCTGCGAAACCCAGTCCATCACCTTCAAGAGCTTCAAAGATAGCCTGAACAAATTCCTGTTCACCATCCCGTTTGATTGTTGGGGCCCGGTAAAAAAA(SEQ ID NO:2).
[0015] Specifically, the gene expressing porcine GM-CSF protein is obtained by the following method:
[0016] With reference to the natural porcine GM-CSF registered in GenBank (accession number: DQ108393.1), according to the expression system (http: / / www.jCat.de / start.jsp), the signal peptide sequence was removed and optimized using JCat software to obtain the gene sequence shown in SEQ ID NO: 2.
[0017] Furthermore, the expression plasmid is the Escherichia coli expression vector pET-32a.
[0018] Furthermore, the expression cell is E. coli BL21 (DE3).
[0019] As a specific embodiment of the present invention, the preparation method of the porcine GM-CSF protein specifically comprises the following steps: recombining the gene sequence expressing the porcine GM-CSF protein into the pET-32a vector to obtain the pET-32a-PGM-CSF recombinant plasmid; transforming the above recombinant plasmid into Escherichia coli, and culturing in LB liquid culture medium until OD 600 When the p-value reaches 0.5-0.6, isopropyl-β-d-thiogalactoside is added to induce expression, the bacteria are collected, centrifuged, resuspended in phosphate buffered saline (PBS), ultrasonically lysed, centrifuged, and the protein is purified using Ni-agarose gel. The purified protein is added to a dialysis bag and then placed in a refolding solution for refolding to obtain porcine GM-CSF protein.
[0020] The process of recombining the gene sequence shown in SEQ ID NO: 2 into the pET-32a vector is as follows: Figure 1 As shown, the double enzyme digestion ligation method was used, and the pET-32a vector and the gene sequence expressing the porcine GM-CSF protein were double-digested with EcoRⅠ and HindⅢ respectively, and the gene sequence after the digestion was connected to the pET-32a vector by homologous recombination to obtain a recombinant expression vector.
[0021] Exemplarily, the culture temperature in LB liquid medium is 35°C to 37°C.
[0022] As a specific embodiment of the present invention, the components of the LB liquid culture medium are: 5 g / L yeast extract, 10 g / L tryptone and 10 g / L NaCl.
[0023] Exemplarily, the final concentration of isopropyl-β-d-thiogalactoside is 0.8 mmol / L to 1.2 mmol / L, and the induction expression time is 4 h to 6 h.
[0024] Exemplarily, the particle size of the nickel-agarose gel resin column is 45-165 μm, and the ligand content is 10-15 μmol.
[0025] Exemplarily, the obtained crude pGM-CSF protein is added to a nickel-agarose gel column, washed with an inclusion body binding buffer, and then eluted with an inclusion body elution buffer, and the eluted protein solution is collected; the obtained protein solution is added to a dialysis bag, and the dialysis bag is placed in a renaturation solution, and renatured at 4°C for 24 hours to obtain pGM-CSF protein, which is stored at -20°C for future use.
[0026] Exemplarily, 10 mL of the refolding solution contains 8.71 g of arginine, 0.0612 g of oxidized glutathione and 0.09 g of reduced glutathione.
[0027] Exemplarily, the renaturation temperature is 2-6° C., the renaturation time is 24-30 hours, and the renaturation solution is replaced every 6-8 hours.
[0028] For example, after the renaturation, the eluted protein solution after renaturation is filtered through a 0.22 μm filter membrane to remove bacteria and ensure that the protein is not contaminated by bacteria.
[0029] In a second aspect, the present invention also provides the use of the above-mentioned composite vaccine adjuvant in the preparation of porcine pseudorabies virus vaccine.
[0030] In a third aspect, the present invention further provides a porcine pseudorabies virus vaccine, comprising a porcine pseudorabies virus antigen and any of the above-mentioned composite vaccine adjuvants.
[0031] Furthermore, each unit dose of porcine pseudorabies vaccine contains 25 μg porcine GM-CSF protein and 500 μg astragalus polysaccharide.
[0032] Astragalus polysaccharide can stimulate macrophages to produce powerful immunomodulatory activity, which can activate the massive production of GM-CSF, thereby improving the body's Th1 and Th2 immune capabilities and making up for the low immune effect of GM-CSF. The combined use of Astragalus polysaccharide and porcine GM-CSF protein can produce a synergistic effect and provide more effective and comprehensive protection for the body.
[0033] It should be noted that the unit dose described in the present invention refers to the conventional single administration (injection) reference amount used in clinical practice.
[0034] In a fourth aspect, the present invention also provides a method for preparing a porcine pseudorabies virus vaccine, comprising the following steps:
[0035] S1, add Span 80 to white oil, mix well, sterilize, and obtain oil phase;
[0036] S2, uniformly mixing the sterilized Tween-80 and the aqueous solution containing the porcine pseudorabies virus antigen to obtain an aqueous phase;
[0037] S3, mixing and emulsifying the oil phase and the water phase in proportion to obtain a vaccine emulsion;
[0038] S4, mixing and emulsifying the vaccine adjuvant and the vaccine emulsion to obtain a porcine pseudorabies virus vaccine.
[0039] The invention provides a method for preparing a porcine pseudorabies virus vaccine, comprising mixing a porcine pseudorabies virus antigen with Tween-80 to prepare an aqueous phase, wherein the porcine pseudorabies virus antigen is dispersed in the Tween-80, so that the porcine pseudorabies virus antigen can be slowly released in the body after the vaccine is injected into the body, thereby facilitating the improvement of the immune effectiveness of the vaccine and achieving longer-lasting immune protection for animals; meanwhile, the vaccine is prepared into a water-in-oil vaccine emulsion, so that the exposure amount of the porcine pseudorabies virus antigen can be further reduced, thereby satisfying the requirement of continuously stimulating the body's immunity and reducing the occurrence of immune side effects.
[0040] Furthermore, in S1, the volume ratio of the Span 80 to the white oil is 7:93 to 5:95.
[0041] Preferably, in S1, the volume ratio of the Span 80 to the white oil is 6:94.
[0042] Furthermore, in S2, the volume ratio of the sterilized Tween-80 to the aqueous solution containing the porcine pseudorabies virus antigen is 0.04:1 to 0.06:1.
[0043] Preferably, in S2, the volume ratio of the sterilized Tween-80 to the aqueous solution containing porcine pseudorabies virus antigen is 0.05:1.
[0044] Specifically, the preparation method of the aqueous solution containing porcine pseudorabies virus antigen is as follows: PRV (1.0×10 7.5 The TCID50) cell strain was added to a formaldehyde solution with a final concentration of 0.1%, and inactivated at 37°C for 48 hours. After the cell test showed that the virus was completely inactivated, the aqueous solution containing the porcine pseudorabies virus antigen was obtained.
[0045] Furthermore, in S3, the volume ratio of the oil phase to the water phase is 1.8:1 to 2.2:1.
[0046] Preferably, in S3, the volume ratio of the oil phase to the water phase is 2:1.
[0047] Furthermore, in S4, the ratio of the vaccine adjuvant to the vaccine emulsion is 525 μg:0.18 mL to 525 μg:0.22 mL.
[0048] Preferably, in S4, the ratio of the vaccine adjuvant to the vaccine emulsion is 525 μg:0.2 mL.
[0049] The composite vaccine adjuvant provided by the present invention can induce the body to produce a high level of neutralizing antibodies, and the highest neutralizing titer is 1:128, which can effectively improve the humoral immune response of inactivated vaccines and significantly enhance the immune effect of vaccines. In addition, the raw materials of vaccine adjuvants are easy to obtain, have good stability, and have few side effects, which provides a new adjuvant option for vaccines and has high value for promotion and application. BRIEF DESCRIPTION OF THE DRAWINGS
[0050] Figure 1 Schematic diagram of constructing a recombinant expression vector from pGM-CSF in the present invention;
[0051] Figure 2 This is a diagram of the analysis and identification of purified pGM-CSF in Example 1 of the present invention, wherein: Figure 2 (A) is the SDS-PAGE analysis, M: protein Maker, 1: pGM-CSF protein; Figure 2 (B) is a Western Blot identification diagram, M: protein Maker, 1: pGM-CSF protein;
[0052] Figure 3 The toxicity of Astragalus polysaccharide and pGM-CSF protein to Vero cells at different dilution multiples, among which, Figure 3(A) is the toxicity of Astragalus polysaccharide to Vero cells, Figure 3 (B) is the toxicity of pGM-CSF protein to Vero cells, where * indicates the cytotoxicity of GM-CSF to Vero cells compared with the control group. -2 The toxicity to Vero cells was significantly different at different dilutions, especially compared with the control group. -1 The toxicity to Vero cells was significantly different at different dilutions;
[0053] Figure 4 The figure is a comparison of the levels of pseudorabies virus glycoprotein B (PRV gB) antibodies in the serum of mice in different experimental groups, among which, *p<0.05, **p<0.01, ***p<0.001 compared with the PRV vaccine group in group 2, # p<0.05, ## p<0.01, ### p < 0.001 compared with group 5 PRV vaccine + pGM-CSF + APS immunization group;
[0054] Figure 5 The figure is a comparison of the neutralizing antibody titers of pseudorabies virus in the mouse sera of different test groups, among which, *p<0.05, **p<0.01, ***p<0.001 compared with the PRV vaccine group in group 2, # p<0.05, ## p<0.01, ### p < 0.001 compared with group 5 PRV vaccine + pGM-CSF + APS immunization group;
[0055] Figure 6 This is a comparison chart of neutralizing antibodies in mouse serum from different test groups detected by plaque assay;
[0056] Figure 7 The comparison chart of IFN-γ concentration in the mouse serum of different experimental groups, among which, *p<0.05, **p<0.01, ***p<0.001 compared with the PRV vaccine group in group 2, # p<0.05, ## p<0.01, ### p < 0.001 compared with group 5 PRV vaccine + pGM-CSF + APS immunization group;
[0057] Figure 8 Comparison of IL-2 concentrations in the serum of mice in different experimental groups, where *p<0.05, **p<0.01, ***p<0.001 compared with the PRV vaccine group in group 2. # p<0.05, ## p<0.01, ###p < 0.001 compared with group 5 PRV vaccine + pGM-CSF + APS immunization group;
[0058] Fig. 9 The figure is a comparison of IL-4 concentrations in the mouse serum of different experimental groups, among which, *p<0.05, **p<0.01, ***p<0.001 compared with the PRV vaccine group in group 2, # p<0.05, ## p<0.01, ### p < 0.001 compared with group 5 PRV vaccine + pGM-CSF + APS immunization group;
[0059] Fig.10 The figure is a comparison of IL-10 concentrations in the mouse serum of different experimental groups, where *p<0.05, **p<0.01, ***p<0.001 compared with the PRV vaccine group in group 2. # p<0.05, ## p<0.01, ### p < 0.001 compared with group 5 PRV vaccine + pGM-CSF + APS immunization group;
[0060] Fig.11 The comparison chart of the total scores of clinical symptoms of mice in different experimental groups after PRV challenge; among them, *p<0.05, **p<0.01, ***p<0.001 compared with the two PRV vaccine groups, # p<0.05, ## p<0.01, ### p < 0.001 compared with group 5 PRV vaccine + pGM-CSF + APS immunization group;
[0061] Fig.12 The figure is a comparison of the survival rates of mice in different experimental groups after PRV challenge; among them, *p<0.05, **p<0.01, ***p<0.001 compared with the PRV vaccine group in group 2, # p<0.05, ## p<0.01, ### p < 0.001 compared with group 5 PRV vaccine + pGM-CSF + APS immunization group;
[0062] Fig.13 The figure is a comparison of the number of viral DNA copies in different tissues of mice in different experimental groups after PRV challenge, among which, *p<0.05, **p<0.01, ***p<0.001 compared with the PRV vaccine group in group 2. # p<0.05, ## p<0.01, ###p < 0.001 compared with group 5 PRV vaccine + pGM-CSF + APS immunization group;
[0063] Fig.14 Comparison of pathological autopsy and pathological sections of different tissues of mice in different experimental groups after PRV infection. DETAILED DESCRIPTION
[0064] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0065] The sources of the main materials used in the present invention are as follows:
[0066] 10% fetal bovine serum and DMEM medium were used to culture Vero cells (DMEM was from WISENT, Canada, and FBS was from OPCEL, Inner Mongolia, China).
[0067] African green monkey kidney cells (Vero) and porcine pseudorabies virus (PRV) were isolated and preserved by our laboratory.
[0068] BL21(DE3) competent cells were purchased from Beijing Biomed Gene Technology Co., Ltd.
[0069] Astragalus polysaccharide (APS) was purchased from Sichuan Hengrui Tongda Biotechnology Co., Ltd.
[0070] Mouse IL-2, IL-4, IL-10, and IFN-γ enzyme-linked immunosorbent assay kits were purchased from Beijing Dongge Biotechnology Co., Ltd.
[0071] Mouse anti-swine gB protein antibody ELISA kit was purchased from Shanghai ELISA Biotechnology Co., Ltd.
[0072] FastReal rapid fluorescence quantitative PCR premix reagent (SYBRGreen) was purchased from Beijing Tiangen Biochemical Technology Co., Ltd.
[0073] If no specific conditions are specified in the present invention, the conventional conditions or the conditions recommended by the manufacturer shall be followed; if no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.
[0074] LB liquid medium: 5 g / L yeast extract, 10 g / L tryptone, and 10 g / L NaCl.
[0075] Renaturation solution: arginine 8.71 g / 10 mL, oxidized glutathione 0.0612 g / 10 mL and reduced glutathione 0.09 g / 10 mL.
[0076] The gene expressing porcine GM-CSF protein with a nucleotide sequence such as SEQ ID NO: 2 in the present invention is obtained by the following method:
[0077] With reference to the natural porcine GM-CSF registered in GenBank (accession number: DQ108393.1), according to the expression system (http: / / www.jCat.de / start.jsp), the signal peptide sequence was removed and optimized using JCat software to obtain the gene sequence shown in SEQ ID NO: 2.
[0078] The mice used in the embodiments of the present invention are SPF-grade healthy female BALB / c mice, 6 weeks old, weighing 30-50 g, purchased from Beijing Huafukang Biotechnology Co., Ltd., with a production unit license number of SCXK (Beijing) 2019-0008. The mouse experiment follows the principles of biosafety and bioethics, and the experiment follows the guidance of the Animal Ethics Committee of Hebei Agricultural University.
[0079] In order to better illustrate the present invention, further examples are given below.
[0080] Example 1
[0081] This embodiment provides a method for preparing pGM-CSF protein, comprising the following steps:
[0082] S1, using EcoRⅠ and HindⅢ to double-digest the pET-28a vector and the gene sequence of pGM-CSF shown in SEQ ID NO:2, and connecting the gene sequence after the digestion to the pET-28a vector by homologous recombination to obtain a recombinant expression vector, which is recorded as pET32a-pGM-CSF;
[0083] S2, transfer 100 μL of the above-mentioned pET32a-pGM-CSF recombinant expression vector into 100 μL of Escherichia coli BL21 (DE3), add it to 150 mL of LB liquid medium, culture it at 37°C until OD600 reaches 0.5, add isopropyl-β-d-thiogalactopyranoside (IPTG) glycoside at a final concentration of 1 mmol / L to induce expression for 4 hours, collect the bacteria, centrifuge at 5000×g and 4°C for 15 minutes, resuspend in 15 mL of phosphate buffered saline (PBS), lyse it by ultrasound (360W, 30%) for 10 minutes, separate the ultrasound product after centrifugation at 4°C and 10000×g for 10 minutes, and obtain the crude pGM-CSF protein;
[0084] S3, add the obtained crude pGM-CSF protein to the nickel-agarose gel column, wash with inclusion body binding buffer, elute with inclusion body elution buffer, and collect the eluted protein solution; add the obtained protein solution to a dialysis bag, place the dialysis bag in a renaturation solution, renature at 4°C for 24 hours, obtain pGM-CSF protein, and store at -20°C for future use.
[0085] The products induced by IPTG were analyzed by SDS-PAGE, and the results showed that the pGM-CSF protein was successfully expressed. The molecular weight of the recombinant pGM-CSF protein was about 32 kDa and the protein was expressed in the form of inclusion bodies. Figure 2 (A) As shown. pGM-CSF expressed by the pET-32a prokaryotic expression vector carries a His tag, so the antibody against the His tag was used to perform Western Blot identification on the expressed and purified pGM-CSF protein. The results are shown in Figure 2 As shown in (B), there is a specific band at 32 kDa, and the band size is consistent with the SDS-PAGE result. The above results prove that the pGM-CSF protein is successfully expressed.
[0086] Example 2
[0087] This embodiment provides a method for preparing a porcine pseudorabies virus vaccine, comprising the following steps:
[0088] Step a, preparation of antigen:
[0089] PRV (1.0×10 7.5 TCID50) cell strains were added to a formaldehyde solution with a final concentration of 0.1% and inactivated at 37°C for 48 hours. During this period, the virus solution was shaken 2 to 3 times at irregular intervals to allow sufficient contact between the virus solution and formaldehyde. After the cell test showed that the virus was completely inactivated, it was refrigerated at 4°C for later use.
[0090] Step b, preparation of vaccine emulsion:
[0091] Add 0.48 mL of Span 80 to 7.52 mL of white oil, sterilize at 0.1 MPa and 121°C to obtain the oil phase;
[0092] Sterilize Tween-80 at 0.1 MPa and 121° C., take 0.2 mL and mix with 4 mL of the antigen solution (containing 4 μL of inactivated antigen) prepared in step a, emulsify, and obtain a vaccine emulsion;
[0093] Step c, preparation of vaccine product:
[0094] Take 0.2 mL of the above vaccine emulsion, add 25 μg of pGM-CSF protein and 500 μg of astragalus polysaccharide, emulsify, and obtain the porcine pseudorabies virus vaccine.
[0095] Drug safety
[0096] Cytotoxicity assay of pGM-CSF protein and astragalus polysaccharide
[0097] The cell counting kit-8 (CCK-8) was used to evaluate the cytotoxicity of porcine GM-CSF protein and astragalus polysaccharide. Vero cell suspension was added to a 96-well plate. After the cells grew into a monolayer, pGM-CSF protein and astragalus polysaccharide were diluted to different concentrations with DMEM containing 2% PBS. pGM-CSF protein was diluted to 4 -1 ~4 -9 Dilution, APS was diluted in a gradient of 5000μg, 2500μg, 1000μg, 500μg, 250μg, and 100μg. The diluted pGM-CSF protein and astragalus polysaccharide were added to the monolayer of Vero cells, and a negative control group (only Vero cell suspension was added, recorded as the control group) and a blank group were set up. The 96-well plate was then incubated in a cell culture incubator for 16 hours, the supernatant was discarded, and a maintenance solution containing 10% CKK8 (DMEM containing 2% FBS) was added. The cell culture plate was incubated at 37°C and 5% CO2 for 1 hour. Finally, the absorbance at 450nm was measured using an enzyme reader, and the cytotoxicity was calculated. The results are as follows: Figure 3 shown.
[0098] The results showed that compared with the control group, under any dilution conditions, the effect of Astragalus polysaccharide on the growth of Vero cells after treatment was not significant. -1 ~4 -2 The viability of Vero cells was significantly reduced at 4 -3 ~4 -9 There was no significant decrease in dilution concentration (p>0.05). 500 μg of Astragalus polysaccharide used in the present invention had no effect on cell viability. Similarly, 25 μg of pGM-CSF protein concentration was 1.6 mg / mL, and at 4 -3 Within the dilution range, no cytotoxicity was produced. These results indicate that the pGM-CSF protein and astragalus polysaccharide composite adjuvant is safe for Vero cells and has no obvious cytotoxic effect on Vero cells.
[0099] Mouse Immunization Test
[0100] 50 BALB / c mice were randomly divided into five groups, 10 mice in each group, and the immunization method was subcutaneous injection in the back. Group 1 was the PBS group (negative control group), inoculated with 0.2mL PBS buffer; Group 2 was the PRV vaccine group, inoculated with 0.2mL of the vaccine emulsion prepared in step b of Example 2; Group 3 was the PRV vaccine + APS group, inoculated with 0.2mL of the vaccine emulsion prepared in step b + 500μg of astragalus polysaccharide; Group 4 was the PRV vaccine + pGM-CSF group, inoculated with 0.2mL of the vaccine emulsion prepared in step b + 25μg pGM-CSF; Group 5 was the PRV vaccine + pGM-CSF + APS group, inoculated with 0.2mL of the vaccine emulsion prepared in step b + 25μg pGM-CSF + 500μg of astragalus polysaccharide. The experimental groups are shown in Table 1.
[0101] Table 1 Grouping of mouse immunization test
[0102]
[0103] A booster immunization was performed on mice at the same dose and in the same manner 14 days after the first immunization. Serum was collected by bleeding from the tip of the tail 7 days and 14 days after the first immunization and 7 days and 14 days after the second immunization, respectively. After standing at 37°C for 2 hours, the blood was centrifuged at 3000 rpm for 5 minutes to separate the serum for subsequent experiments.
[0104] 1. Indirect ELISA to detect the level of PRV gB protein antibody in the serum of immunized mice
[0105] One-step indirect ELISA was used to detect the level of PRV gB protein antibody in the serum of immunized mice. The content of PRV gB protein antibody in the serum was detected and calculated according to the instructions of the mouse anti-swine gB protein antibody enzyme-linked immunosorbent assay kit. The results are shown in Table 2 and Figure 4 shown.
[0106] Table 2 Content of PRV gB protein antibody in mouse serum
[0107]
[0108]
[0109] Note: *p<0.05, **p<0.01, ***p<0.001 compared with the PRV vaccine group in group 2. # p<0.05, ## p<0.01, ### p<0.001 compared with group 5 PRV vaccine+pGM-CSF+APS immunization group.
[0110] The results showed that on the 7th day, there was no difference between the three groups of Group 3, Group 4 and Group 5, but they were all significantly higher than Group 2 (vaccine group) and Group 1 (negative control group) (p < 0.001), and the antibody level of the vaccine group alone was significantly higher than that of the negative control group (p < 0.05). On the 14th and 21st days, the PRV gB antibody level of Group 5 (compound adjuvant group) was significantly higher than that of the two single adjuvant groups (Group 3 and Group 4) (p < 0.05). The antibody levels of Group 3, Group 4 and Group 5 were all significantly higher than that of Group 2 alone (p < 0.01). On the 28th day, the antibody levels between Group 4 and Group 5 were significantly different (p < 0.01), and there was no significant difference between Group 3 and Group 5, but the PRVgB antibody level of Group 3 was lower than that of Group 5. The overall trend of the PRV gB protein antibody level determined by the mouse immunization test gradually increased on the 7th, 14th, and 21st days, and reached the highest level on the 21st day, but gradually decreased from the 21st to the 28th day.
[0111] 1.2 Detection of neutralizing antibodies
[0112] Neutralizing antibodies against PRV were detected in a cell-based assay using the fixed virus dilution serum method.
[0113] The mouse serum samples inactivated at 56°C for 30 min were diluted 2-fold with DMEM containing 2% PBS and then diluted with 200 TCID 50 Mix equal volumes of PRV, incubate at 37°C for 1 hour, discard the supernatant, add new DMEM containing 2% FBS, and culture in a 37°C, 5% CO2 incubator for 72 hours. Calculate according to the Reed-Muench method, and the highest serum dilution factor that makes 50% of cells not lesion is the serum neutralization titer. During the experiment, the group that only added 200TCID50 of PRV was set as the virus group, and the group that only added DMEM containing 2% PBS was set as the negative control group. The results are shown in Table 3 and Figure 5 shown.
[0114] The calculation formula of neutralization titer is as follows:
[0115] Distance ratio = (percentage above 50% - 50%) / (percentage above 50% - percentage below 50%);
[0116] lg (neutralizing antibody titer) = logarithm of dilution above 50% + distance ratio × logarithm of dilution factor;
[0117] Neutralizing antibody titer = antilogarithm of lg(neutralizing antibody titer)
[0118] Neutralizing antibody titer = log2 (neutralizing antibody titer)
[0119] Table 3 Neutralizing antibody titer
[0120]
[0121] Note: *p<0.05, **p<0.01, ***p<0.001 compared with the PRV vaccine group in group 2. # p<0.05, ## p<0.01, ### p<0.001 compared with group 5 PRV vaccine+pGM-CSF+APS immunization group.
[0122] Serum samples were collected on days 7, 14, 21, and 28 after immunization for neutralization test determination. The results showed that on day 7, neutralizing antibodies were detected in all groups, and the neutralizing antibody level in group 5 (compound adjuvant group) was significantly higher than that in groups 3 and 4 (p < 0.01). On days 14 and 21, the neutralizing antibody level in the compound adjuvant group was significantly higher than that in groups 3 and 4 (p < 0.05). On day 28, there was no difference between the compound adjuvant group and the single adjuvant immunization group 3, but the average level was higher than that in the single immunization group; the neutralizing antibody level produced by the compound adjuvant group was significantly higher than that in group 4 (p < 0.05). The neutralizing antibody level in the compound adjuvant group gradually increased from day 7 to day 21 and reached the highest on day 21, with a peak average titer of 7.56log2, and then began to decline until day 28, with an average neutralization titer of 6.58log2. This shows that the use of composite adjuvants in PRV inactivated vaccines can induce the body to produce higher levels of neutralizing antibodies.
[0123] 3. Plaque Assay
[0124] Vero cells were inoculated in 6-well plates. When the cells were fused to a monolayer, the culture medium was discarded and a 200 TCID 50 0.1 mL of DMEM containing 2% PBS and 0.1 mL of 10-fold diluted mouse serum (10 -1 -10 -4 ) was added to Vero cells and incubated at 37°C for 2h. Then the supernatant was discarded, the cells were washed with PBS, and 2mL of 0.4% CMC-Na solution preheated at 37°C was quickly added to each well. During the addition process, the cells should be prevented from drying out. The cell culture plate was cultured in a cell culture incubator. After 96h, the culture medium was discarded, and each well was filled with 10% formaldehyde solution. After fixing for 12h, the wells were rinsed with gently running water. 300μL of 0.35% crystal violet solution was added to all wells, and the wells were stained on a shaker for 8min. Then, the cell plate was rinsed with gently running water, and then the 6-well plate was placed at 50°C for drying and photographed. The results are shown in Figure 6 shown.
[0125] See also Figure 6As shown, the plaques of mice immunized with PRV vaccine in group 5 with pGM-CSF and APS were the least, and the plaques of the two single adjuvant groups, group 3 and group 4, were less than those of the single vaccine group in group 2, and the plaques of the single vaccine group were significantly less than those of the negative control group in group 1. The above results show that the combined application of the composite adjuvant pGM-CSF and APS in PRV vaccine can enhance and maintain the production of neutralizing antibodies, effectively improve the humoral immune efficacy of inactivated vaccines, and is superior to the application of single adjuvants.
[0126] 4. Indirect ELISA to detect cytokines in serum of immune mice
[0127] According to the instructions of the mouse IL-2, IL-4, IL-10, and IFN-γ enzyme-linked immunosorbent assay kit of Dongge Company, the IL-2, IL-4, IL-10, and IFN-γ cytokines in the serum of mice on the 7th, 14th, 21st, and 28th day after immunization were detected and the contents were calculated. The results are shown in Tables 4 to 7 and Figure 7 to Figure 10 shown.
[0128] Table 4 IFN-γ content in mouse serum
[0129]
[0130] Note: *p<0.05, **p<0.01, ***p<0.001 compared with the PRV vaccine group in group 2. # p<0.05, ## p<0.01, ### p<0.001 compared with group 5 PRV vaccine+pGM-CSF+APS immunization group.
[0131] Table 5 IL-2 concentration in mouse serum
[0132]
[0133] Note: *p<0.05, **p<0.01, ***p<0.001 compared with the PRV vaccine group in group 2. # p<0.05, ## p<0.01, ### p<0.001 compared with group 5 PRV vaccine+pGM-CSF+APS immunization group.
[0134] Table 6 IL-4 concentration in mouse serum
[0135]
[0136] Note: *p<0.05, **p<0.01, ***p<0.001 compared with the PRV vaccine group in group 2. # p<0.05,## p<0.01, ### p<0.001 compared with group 5 PRV vaccine+pGM-CSF+APS immunization group.
[0137] Table 7 IL-10 concentration in mouse serum
[0138]
[0139] Note: *p<0.05, **p<0.01, ***p<0.001 compared with the PRV vaccine group in group 2. # p<0.05, ## p<0.01, ### p<0.001 compared with group 5 PRV vaccine+pGM-CSF+APS immunization group.
[0140] The results showed that compared with the negative control group in group 1, all four groups from group 2 to group 5 induced the body to produce IL-2, and the level of IL-2 continued to rise from the 7th day to the 28th day. The level of IL-2 induced by group 5 was significantly higher than that of other groups (p < 0.01), among which the IL-2 level was the highest on the 28th day, which was 199.8pg / mL. Similarly, compared with the negative control group in group 1, all four groups from group 2 to group 5 induced the body to produce IFN-γ, and the level of IFN-γ induced by group 5 was significantly higher than that of other groups (p < 0.01), and showed a gradual upward trend from the 7th day to the 28th day, reaching the highest level on the 28th day, with a concentration of 516.3pg / mL. The above results show that the use of pGM-CSF protein and APS in the preparation of PRV vaccine effectively induced the mouse body to produce high levels of Th1 cytokines and improved the efficacy of cellular immunity.
[0141] In addition, in terms of humoral immunity, compared with the negative control group in group 1, all four groups from group 2 to group 5 induced the body to produce IL-4, which showed a continuous upward trend from the 7th day and continued to reach the highest level on the 28th day. The composite adjuvant group in group 5 was still able to produce high levels of IL-4 (p < 0.01), with a concentration of 99.1 pg / mL. Similarly, compared with the negative control group in group 1, the PRV inactivated vaccine with the addition of pGM-CSF and APS adjuvants greatly increased the level of IL-10 in the mouse body (p < 0.01), and it continued to rise from the 7th day to the 28th day to reach the highest level, with the highest concentration of IL-10 being 250 pg / mL. The above results show that the use of pGM-CSF protein and APS in combination with the PRV inactivated vaccine greatly improved the mouse body's production of high levels of Th2 cytokines and improved the body's humoral immunity.
[0142] 5. Tissue Viral Load Detection
[0143] 14 days after the mouse booster immunization test, the mice in each group were challenged with 200 μL of PRV virus at a titer of 103 TCID50 after blood was collected from the tail tip of the mice in each group. The clinical symptoms of the mice in each group after challenge were observed for 14 consecutive days and scored according to the following criteria:
[0144] 0 = no symptoms; 1 = loss of appetite, lethargy, rough coat, lack of weight bearing ability, scratches, scratched skin, neurological symptoms; 5 = death.
[0145] After the challenge, all surviving mice were killed 14 days after the challenge, and spleen, lung and brain were taken. Tissues were collected immediately after the mice died. Viral DNA was extracted from the tissues and the gH gene was amplified using the qPCR method. The primers used for qPCR are shown in Table 8.
[0146] Table 8 Amplification of PRV-gH gene PCR and qPCR primer sequences
[0147]
[0148] The symptom scores of mice in each group are as follows Fig.11 As shown, the survival rate is Fig.12 The viral DNA copy numbers in different tissues are shown in Table 9 and Fig.13 shown.
[0149] The negative control group in group 1 showed severe clinical symptoms after the virus attack, including restlessness, itching, scratching, biting of facial skin, skin damage with tissue damage, bleeding, etc. At the same time, neurological symptoms were observed in the negative control group. Although the mice in groups 2 to 5 showed clinical symptoms, their symptoms were milder than those of the mice in the negative control group. All clinical symptoms were expressed by clinical scores. The results showed that whether it was the composite biological adjuvant in group 5 or the single adjuvant in groups 3 and 4 or even the single immunization group in group 2, the clinical scores of the above four groups were significantly lower than those of the negative control group on days 1-5 (p < 0.001). Because all the mice in the negative control group died on day 4, the clinical score was 0 during the subsequent test period. However, during the entire test period, the clinical symptom scores of the composite adjuvant group in group 5 were significantly lower than those of other groups.
[0150] In addition, the negative control group began to die on the third day after the challenge, and all died on the fourth day. However, throughout the experiment, the clinical symptom scores of the fifth group of composite adjuvants were always lower than those of other immunization groups. The negative control group began to die on the third day after the challenge, and all died on the fourth day. In contrast, mice in the single immunization group died from the sixth to the ninth day, but still had a survival rate of nearly 41.7%. In the single adjuvant vaccines of groups 3 and 4, deaths began to occur from the seventh day, and the final survival rates were 77.8% and 75%, respectively. In contrast, in the fifth group given the composite adjuvant, only one mouse died on the eighth day, and the final survival rate was 85.7%. These results show that APS and pGM-CSF adjuvants improve the immune protection of the vaccine to a certain extent, prolong the antigen release time, and improve the survival rate of mice. Similarly, the vaccine with the addition of composite adjuvants enhances the vaccine efficacy, prolongs the antigen release time, and significantly improves the survival rate of mice. The above studies show that the inactivated PRV vaccine has a certain protective effect. The addition of various adjuvants enhanced the immunogenicity of the vaccine and significantly reduced the mortality and incidence of clinical neurological symptoms in mice.
[0151] To further study the effect of adding pGM-CSF and APS combined adjuvants on the replication of PRV inactivated vaccine in different mouse tissues, we collected spleen, lung, and brain tissues from mice and used qPCR to determine the number of viral DNA copies in the tissues.
[0152] Table 9 The number of viral DNA copies in different tissues of mice in each group after PRV challenge
[0153]
[0154] Note: *p<0.05, **p<0.01, ***p<0.001 compared with the PRV vaccine group in group 2. # p<0.05, ## p<0.01, ### p<0.001 compared with group 5 PRV vaccine+pGM-CSF+APS immunization group.
[0155] The results showed that the number of viral DNA copies in the tissues of mice immunized with the PRV vaccine + pGM-CSF + APS group was significantly lower than that in the negative control group (p < 0.001), among which the number of viral DNA copies in the spleen decreased by approximately 2.38 log, the number of viral DNA copies in the lung tissue decreased by approximately 2.73 log, and the number of viral DNA copies in the brain tissue decreased by approximately 1.34 log.
[0156] 6. Histopathological Examination
[0157] The surviving mice in the group were euthanized and dissected on the 14th day after the challenge. The spleen, lungs, and brain were removed and fixed with 10% formalin, embedded in wax, cut into transverse sections, and stained with hematoxylin and eosin (H&E). Fig.14 shown.
[0158] Mice were killed 14 days after infection, and the lesions of spleen, lung and brain were observed and photographed during autopsy ( Fig.14 A). Histopathological observations showed that compared with groups 1 and 2, the pulmonary hemorrhage in groups 3, 4, and 5 was relatively mild, with group 5 having the least hemorrhage ( Fig.14 A). Compared with the negative control group in group 1, group 2 had less bleeding and milder lesions. The negative control group had obvious lesions in the lungs after the virus attack, all of which were necrotic foci. Histopathological sections showed that the lungs of mice in groups 3, 4, and 5 all had varying degrees of hemorrhagic lesions ( Fig.14 B). The degree of lesions in group 5 was lower than that in groups 3 and 4. The interstitial lung thickening was observed in groups 3 and 4, and in group 5. The interstitial lung thickening, inflammatory cell infiltration, and a large number of bleeding spots were significantly increased in the negative control group. Compared with the negative control group after the virus attack, group 2 had fewer bleeding spots and less interstitial thickening. However, compared with groups 3, 4, and 5, group 2 had a higher incidence of bleeding spots and thicker interstitial lungs ( Fig.14 B).
[0159] In the negative control group of group 1, the spleen of mice shrank after the virus attack, the color changed from dark red to yellow, the blood vessels contracted and became smaller, and the lesions were obvious ( Fig.14 A). No obvious pathological changes were found in groups 3, 4, and 5, and a small number of multinucleated giant cells (MGCs) were observed in the spleen of group 2. The negative control group in group 1 developed severe hemorrhagic congestion after the virus attack, and a large number of MGCs appeared in the spleen ( Fig.14 B).
[0160] The mice in the negative control group showed the most significant brain tissue damage after the virus attack, accompanied by obvious dilation of meningeal blood vessels and additional bleeding points. The meningeal blood vessels of mice in groups 2, 3, and 4 were slightly dilated and congested, while the meningeal blood vessels of mice in group 5 were not significantly dilated and congested ( Fig.14 A). In addition, no pathological changes such as bleeding and necrosis were observed in the brain tissue of mice in groups 3, 4, and 5. The negative control group had a high degree of inflammatory cell infiltration after the virus attack, with a large number of bleeding spots and the presence of tube sheath phenomenon ( Fig.14 B). Compared with the negative control group in group 1, the number of bleeding spots in group 2 was significantly reduced ( Fig.14 B).
[0161] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A composite vaccine adjuvant, characterized in that: It comprises porcine GM-CSF protein and astragalus polysaccharide, wherein the amino acid sequence of the porcine GM-CSF protein is shown in SEQ ID NO:
1.
2. The composite vaccine adjuvant according to claim 1, characterized in that The method for preparing the porcine GM-CSF protein comprises the following steps: recombining the gene sequence expressing the porcine GM-CSF protein into an expression plasmid to obtain a recombinant plasmid; and transforming the recombinant plasmid into an expression cell for expression to obtain the porcine GM-CSF protein.
3. The composite vaccine adjuvant according to claim 2, characterized in that The gene sequence expressing porcine GM-CSF protein is shown in SEQ ID NO:
2.
4. The composite vaccine adjuvant according to claim 2, characterized in that The expression plasmid is the Escherichia coli expression vector pET-32a.
5. The composite vaccine adjuvant according to claim 2, characterized in that The expression cell is E. coli BL21 (DE3).
6. Use of the composite vaccine adjuvant according to any one of claims 1 to 5 in the preparation of porcine pseudorabies virus vaccine.
7. A porcine pseudorabies virus vaccine, characterized in that: The invention comprises porcine pseudorabies virus antigen and the composite vaccine adjuvant according to any one of claims 1 to 5.
8. The porcine pseudorabies virus vaccine according to claim 7, characterized in that: Each unit dose of porcine pseudorabies vaccine contains 25μg porcine GM-CSF protein and 500μg astragalus polysaccharide.
9. The method for preparing the porcine pseudorabies virus vaccine according to claim 7 or 8, characterized in that: The steps include: S1, add Span 80 to white oil, mix well, sterilize, and obtain oil phase; S2, uniformly mixing the sterilized Tween-80 and the aqueous solution containing the porcine pseudorabies virus antigen to obtain an aqueous phase; S3, mixing and emulsifying the oil phase and the water phase in proportion to obtain a vaccine emulsion; S4, mixing and emulsifying the vaccine adjuvant and the vaccine emulsion to obtain a porcine pseudorabies virus vaccine.
10. The method for preparing the porcine pseudorabies virus vaccine according to claim 7, characterized in that: In S1, the volume ratio of the Span 80 to the white oil is 7:93 to 5:95; and / or In S2, the volume ratio of the sterilized Tween-80 to the aqueous solution containing the porcine pseudorabies virus antigen is 0.04:1 to 0.06:1; and / or In S3, the volume ratio of the oil phase to the water phase is 1.8:1 to 2.2:1; and / or In S4, the ratio of the vaccine adjuvant to the vaccine emulsion is 525 μg:0.18 mL to 525 μg:0.22 mL.
